Renal Denervation for the Treatment of Hypertension: A Pilot Safety and Efficacy Study
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02672462
Recruitment Status : Unknown
Verified February 2016 by Shanghai Golden Leaf MedTec Co. Ltd. Recruitment status was: Recruiting
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Layout table for eligibility information
Ages Eligible for Study:
18 Years to 75 Years (Adult, Older Adult)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
Ages of 18 to 75, male or female;
Main renal artery, with or without accessary renal arteries, with length
Patients who have not taken any anti-hypertensive drugs or have been off drugs for at least 2 weeks, with mean SBP ≥150mmHg and
180mmHg based on at least 3 office blood pressure measurements, or ASBP≥135mmHg and ≤170mmHg based on 24 hr blood pressure monitoring;
Agrees to take part in the trial and signs the written, informed consent.
Renal artery abnormalities that are inappropriate for the procedure;
Pregnant or plan to become pregnant;
History of orthostatic hypotension;
Type I diabetes;
Only one kidney or prior kidney transplantation;
Bleeding tendency or other coagulation related diseases;
Acute or severe systemic infection;
Prior renal artery interventional procedures or prior RDN treatment;
History of stroke or TIA;
Malignant tumor or end-stage illnesses;
Acute coronary events within 2 weeks;
Other conditions that deem unsuitable for the procedure, in the opinions of investigators.